Play video
-
Triple antigen - a more promising vaccine candidate for protection against COVID-19 variants
- Targets 3 SARS CoV-2 virus surface proteins, including proteins less susceptible to mutation, making our vaccine a better candidate to provide protection even against emerging mutated viruses.
- Demonstrated (in preclinical and GLP-Tox studies) to be safe, efficacious and well tolerated at normal to high doses, and generates high titres of neutralizing antibodies
-
Oral vaccine should improve efficacy, takes burden off health care systems
- Cuts out the need for freezing equipment for transportation & storage
- Easy accessibility results in better population coverage (especially for those who fear needles)
- Minimizes cost of training and mobilizing health care personnel
- Eliminates occupational needle-stick injuries
- Eliminates bio-hazardous waste problem
-
Clinical trial preparations are underway with studies expected to commence H1 2021
In a pilot animal study, the oral COVID-19 vaccine promoted both systemic immunity through Immunoglobulin G (IgG), the most common antibody in blood and bodily fluids that protects against viral infections, and Immunoglobulin A (IgA), which protects the respiratory and gastrointestinal tracts against infection.
Oravax is based on cutting edge technology from
Oramed Pharmaceuticals & Premas Biotech.
Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions
for drugs currently delivered via injection. Oramed’s proprietary Protein Oral Delivery (POD™)
technology allows for the oral delivery of therapeutic proteins and vaccines.
www.oramed.com.
Premas Biotech is an innovative developer and manufacturer of novel biotherapeutic & vaccine candidates.
Premas' key areas of focus include: infectious diseases, cancer, metabolic disorders and inflammation.
Premas’s novel D-Crypt™ platform technology focuses on difficult to express proteins .
www.premasbiotech.com